CPL makes progress with flu/rabies vaccines
CPL Biologicals, Novavax' joint venture (JV) with Cadila Pharmaceuticals in India, has claimed significant progress with its vaccine-development programmes in 2011 and is now preparing to start work on clinical studies of vaccine candidates to prevent influenza and rabies during 2012 and 2013, respectively. CPL was established in 2009 to combine Novavax' vaccine technology and Cadila's product development and manufacturing expertise to develop vaccine candidates from both companies and manufacture and market them in India. Novavax retains rights to products developed for markets outside of the country.
A rabies vaccine candidate developed by Novavax claims to show "great promise" in preclinical testing. CPL completed positive preclinical immunogenicity studies of the rabies G-protein nanoparticle vaccine and has recently received approval from the Review Committee on Genetic Manipulation (RCGM) to begin toxicology studies of this vaccine prior to initiating human trials. The RCGM is responsible for regulating preclinical and clinical testing of recombinant vaccines, diagnostics and biologics in India.